Cytokines as the major mechanism of mesenchymal stem cell clinical activity: Expanding the spectrum of cell therapy

Israel Medical Association Journal

Volumn 11, Issue 4, 2009, Pages 209-211

  Horwitz, Edwin M ^a   Prather, William R ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PLURISTEM THERAPEUTICS INC   (Israel)

Author keywords

Cell therapy; Cytokine cell processing; Mechanism of action; Mesenchymal stem cells

Indexed keywords

CYTOKINE;

ACUTE HEART INFARCTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; BONE DISEASE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL ISOLATION; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CYTOKINE RELEASE; ENGRAFTMENT; GENETIC DISORDER; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIMB BLOOD FLOW; LIMB ISCHEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; OSTEOGENESIS IMPERFECTA; PROTEIN EXPRESSION; TISSUE REGENERATION; TISSUE REPAIR; TREATMENT INDICATION;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CYTOKINES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION;

EID: 67549112705     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Horwitz E, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7: 393-5.
2. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-17.
3. Wagner W, Feldmann RE Jr., Seckinger A, et al. The heterogeneity of human mesenchymal stem cell preparations - evidence from simultaneous analysis of proteomes and transcriptomes. Exp Hematol 2006; 34: 536-48.
4. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6: 230-47.
5. Owen M. Marrow stromal stem cells. J Cell Sci Suppl 1988; 10: 63-76.
6. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991; 9: 641-50.
7. Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med 2001; 7: 259-64.
8. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-4.
9. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557-64.
10. Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932-7.
11. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-41.
12. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-86.
13. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110: 2764-7.
14. Prather WR, Toren A, Meiron M, et al. The role of placental-derived adherent stromal cells (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy 2009. In press.
15. Zimmet JM, Hare JM. Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy. Basic Res Cardiol 2005; 100: 471-81.
16. Chopp M, Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002; 1: 92-100.
17. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106: 1755-61.
18. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000; 28: 875-84.
19. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24: 1030-41.
20. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 2006; 198: 54-64.